Recital 47, Regulation (EU) 2026/2348

In force

The application for the renewal of the approval of the active substance tembotrione was submitted on 26 July 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 22 April 2026 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in October 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 29 months, until 31 May 2029.